Back

AXIS Medical Education, Inc.

  • Molecular Targeted Therapy

HER2 in Solid Tumors: From Pathology to Personalized Treatment Plans

The goal of this educational initiative is to equip oncology care teams with the knowledge and clinical decision-making tools needed to optimize the selection, sequencing, and safety management of HER2-directed ADCs across tumor types. Despite the expanded indications and tumor-agnostic approvals of agents such as T-DXd, significant gaps remain in HER2 reassessment practices, therapeutic sequencing frameworks, and adverse event management particularly in non-breast solid tumors such as gynecologic, gastrointestinal, and lung cancers.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1 creditAAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Regularly Scheduled Series
  • Credit · Up to 1 credit
  • Commercial Support
  • Released
    Apr 30, 2026
  • Last day to claim credit
    Jan 1, 2027 3 months left